Appearance and solubility

What does an appearance test actually check?

ICH Q6A lists description first among the tests generally applicable to new drug substances: a qualitative statement about the state (solid, liquid) and colour (ICH Q6A). ICH Q6B asks for the same for biotechnological substances, and for finished products adds clarity (ICH Q6B).

For synthetic peptides, the European Medicines Agency's draft guideline lists appearance, plus appearance of solution where relevant, as the first typical specification test, and expects solubility in different media to be among the general properties reported (EMA draft guideline on synthetic peptides, 2023).

What does the freeze-dried cake tell you?

In a freeze-dried vial, the solution was frozen and the ice removed under vacuum, leaving a porous solid called a cake. If the product gets too warm during the main drying stage, the structure can collapse or melt back. A 2023 review on freeze-drying process design explains that exceeding the collapse temperature leads to a less elegant cake and can compromise other quality attributes, including residual water content (Pharmaceutical Research, 2023).

The same review cites publications showing collapse does not necessarily lead to potency losses, that (micro)collapse could improve long-term stability, and that product quality can remain within specification when the cake is not pharmaceutically elegant. The studies it cites were on a small-molecule product and on proteins, not peptides. A shrunken cake is a reason to look harder, not a verdict.

How is visual inspection done properly?

Regulated manufacturers inspect against defined conditions, not a quick glance. A 2025 review of freeze-drying in human drug applications and inspections found that visual inspection of freeze-dried products was the most common source of FDA Form 483 inspection observations in that area, citing problems such as inadequate defect libraries for training and not following USP recommendations on inspection time per vial, light intensity, operator fatigue and black and white backgrounds (AAPS Open, 2025). The same review points to USP chapters <790> and <1790> as resources.

A report that describes appearance should say what was seen under what conditions, ideally with a photograph. "Conforms" alone means only that the analyst saw nothing out of line with the stated description.

What does a solubility test add?

Incomplete dissolution or haze in a stated solvent can point to aggregation or foreign material. The EMA draft guideline notes that aggregation can occur in synthetic peptides and should be investigated during stability.

Complete dissolution also matters for the other tests. Recommendations for peptides used in mass spectrometry assays stress that for characterisation by HPLC-UV, MALDI and especially amino acid analysis, the peptide must be completely dissolved (Hoofnagle and colleagues, Clinical Chemistry, 2016). A sample that only partly dissolves can give a low amount result for reasons that have nothing to do with how much peptide was in the vial.

Why record appearance at all if it cannot prove identity?

Because change is informative. ICH Q6A says that if the state or colour of a substance changes during storage, the change should be investigated. A record of how a vial looked on arrival gives a fixed reference point: if a later vial from the same batch looks different, that difference is evidence, even though neither observation says what the peptide is.

It is also the only check that sees the vial whole before it is opened. Cracked glass, a loose crimp, a missing cake or foreign particles never show on a chromatogram.

Does Tested.ph offer appearance and solubility testing?

Not as a separate test. When testing opens, the partner laboratory's analysis covers identity, purity and amount, with endotoxin as an option. The lesson on what a peptide test can tell you and our guide to telling if tirzepatide is real explain why looking at a vial cannot replace a chemical test.